Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

Figure 6

ROC curve analysis for the cytokine-based model in predicting response to bortezomib treatment in MM patients. At the optimal cut-off value of 0.53, the sensitivity and specificity reached 80.5% and 79.3%, respectively.